The hyperparathyroidism treatment market comprises drugs, imaging tests, and surgical procedures used for hyperparathyroidism disorder management. Hyperparathyroidism refers to the abnormal elevated levels of parathyroid hormone in the blood that leads to excess calcium in the body. The main treatments for hyperparathyroidism include bisphosphonates, calcimimetics, and surgery. Bisphosphonates and calcimimetics help control calcium levels whereas surgery helps in parathyroid gland removal in severe cases.
The Global Hyperparathyroidism Treatment Market is estimated to be valued at USD 780.1 Mn in 2024 and is expected to reach USD 991.2 Mn by 2031, growing at a compound annual growth rate (CAGR) of 6.9% from 2024 to 2031.
Key Takeaways
Key players operating in the hyperparathyroidism treatment are AbbVie, Entera Bio Ltd., Teva Pharmaceuticals, Amgen, and Sun Pharmaceutical.
The key opportunities in the hyperparathyroidism treatment market include growing burden of primary hyperparathyroidism and increasing awareness. Also, ongoing research for developing new targeted treatment options presents significant room for Hyperparathyroidism Treatment Market Growth.
Geographically, North America dominates the global market and is expected to continue its dominance form 2024-2029. However, Asia Pacific region is expected to witness highest growth owing to improving healthcare infrastructure and increasing healthcare spending.
Market Drivers
The increasing prevalence of primary hyperparathyroidism is the major factor driving the growth of the hyperparathyroidism treatment market. As per estimates, primary hyperparathyroidism affects over 150 per 1,00,000 people globally. Moreover, advancing age further raises the risk of developing this endocrine disorder. Thus, rising geriatric population poses as an opportunity for market players in the forecast period.
PEST Analysis
Political: Government regulations related to approval of new drugs and pricing can impact the Hyperparathyroidism Treatment market.
Economic: Financial prospects of patients and reimbursement policies affect sales volumes in this market.
Social: Rising awareness among patients regarding early diagnosis and treatment options is a major driver for market growth.
Technological: Advancements in drug molecule design and imaging techniques aid in improved disease management. Gene therapy and tissue engineering also show promise for more effective treatments.
Geographical Regions with High Market Concentration
Currently, North America accounts for the largest share of the global Hyperparathyroidism Treatment market in terms of value. This can be attributed to the strong healthcare infrastructure and reimbursement systems in the region coupled with growing patient awareness levels. Europe is another major revenue generator for market players.
Fastest Growing Regional Market
The Asia Pacific region is poised to witness the fastest growth over the forecast period owing to increasing healthcare spending, growing geriatric population, and improving diagnostic capabilities across emerging countries such as China and India. Rising living standards are also expanding the potential patient pool in the Asia Pacific Hyperparathyroidism Treatment market.
Get This Report in Japanese Language: 副甲状腺機能亢進症治療市場
Get This Report in Korean Language: 부갑상선기능항진증 치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
